Topical ruxolitinib for prebullous phase of immune checkpoint Inhibitor–Induced bullous pemphigoid

Ines Lederbogen, Barbara Meier-Schiesser · 2026

Read Topical ruxolitinib for prebullous phase of immune checkpoint Inhibitor–Induced bullous pemphigoid by Ines Lederbogen, Barbara Meier-Schiesser (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13628655.txt.

Description

Ines Lederbogen and Barbara Meier-Schiesser report a skin side effect of cancer immune therapy treated with a cream, in this 2026 case report. The patient, a man in his eighties, received an immune drug for skin cancer on his scalp. The drug, which releases the immune system against tumors, can also turn it against the skin. He developed an itchy rash in the early stage before blisters form, a condition called bullous pemphigoid.

Standard care relies on steroids and drugs that suppress the whole immune system, which can clash with cancer treatment. The authors instead used a cream with ruxolitinib, a drug that blocks a signaling pathway linked to blistering diseases. Treating only the skin may calm the reaction while leaving the cancer therapy's power intact. The case adds an option for a growing problem, as immune drugs spread through cancer care.

Catalog record

CREATORInes Lederbogen, Barbara Meier-Schiesser
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE8 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13628655

Browse the full library · About the Tower of Babel